- Trials with a EudraCT protocol (296)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
296 result(s) found for: Screen time.
Displaying page 5 of 15.
EudraCT Number: 2021-001811-94 | Sponsor Protocol Number: M18-868 | Start Date*: 2022-01-28 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Adva... | |||||||||||||
Medical condition: C-Met overexpressing EGFR wildtype, non-squamous non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) BE (Trial now transitioned) HU (Completed) FR (Trial now transitioned) RO (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000929-22 | Sponsor Protocol Number: CRI109244 | Start Date*: 2007-07-06 | |||||||||||
Sponsor Name:GlaxoSmithKline R & D Limited | |||||||||||||
Full Title: A double-blind, randomised, placebo controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF-1 antagonists GSK561679 and GW876008 on meal induced cortisol respo... | |||||||||||||
Medical condition: Irritable Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005024-40 | Sponsor Protocol Number: NPP100023 | Start Date*: 2005-04-06 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LAMOTRIGINE 200-400MG/DAY COMPARED WITH PLACEBO IN SUBJECTS WITH PAINFUL DIA... | ||
Medical condition: Painful Diabetic Neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) LV (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-011318-22 | Sponsor Protocol Number: H6D-EW-LVIJ | Start Date*: 2010-05-07 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: Impact of Tadalafil (LY450190) Once a Day or Tadalafil On Demand Compared to Sildenafil Citrate On Demand on Treatment Discontinuation in Patients with Erectile Dysfunction who are Naïve to PDE5 In... | |||||||||||||
Medical condition: Erectile Dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) PT (Completed) GB (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016457-18 | Sponsor Protocol Number: E05-CL-3001 | Start Date*: 2010-07-20 | |||||||||||
Sponsor Name:Astellas Pharma Europe Ltd | |||||||||||||
Full Title: A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain | |||||||||||||
Medical condition: Peripheral Neuropathic Pain in Postherpetic Neuralgia (PHN), Painful HIV-Associated Neuropathy (HIV-AN), Peripheral Neuropathic Injury (PNI), Idiopathic Small Nerve Neuropathy (ISNN) or other Perip... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) FR (Completed) BE (Completed) GB (Completed) CZ (Completed) FI (Completed) ES (Completed) AT (Completed) IT (Completed) HU (Completed) NL (Completed) SK (Completed) PL (Completed) SI (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003579-11 | Sponsor Protocol Number: TRX4_DM_004_EU_06 | Start Date*: 2007-03-23 | |||||||||||
Sponsor Name:TolerRx, Inc. | |||||||||||||
Full Title: Tolerability and Safety of Multiple Dose Regimens of TRX4 Anti-CD3 Monoclonal Antibody in Type 1 Diabetes Mellitus | |||||||||||||
Medical condition: Type I Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000346-19 | Sponsor Protocol Number: HP-CD-CL-2003 | Start Date*: 2018-06-04 | |||||||||||
Sponsor Name:Herantis Pharma Plc | |||||||||||||
Full Title: A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-C... | |||||||||||||
Medical condition: Idiopathic Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003688-25 | Sponsor Protocol Number: INS1007-301 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibros... | |||||||||||||
Medical condition: Non-Cystic Fibrosis Bronchiectasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) DK (Completed) NL (Completed) IE (Completed) HU (Completed) GR (Completed) PL (Completed) BG (Completed) LT (Prematurely Ended) SK (Completed) AT (Completed) FR (Completed) EE (Prematurely Ended) BE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005040-10 | Sponsor Protocol Number: PRO045-CLIN-01 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:BioMarin Nederland B.V. | |||||||||||||
Full Title: A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple subcutaneous doses of PRO045 in subjects with Duchenne muscular dystrophy | |||||||||||||
Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022307-22 | Sponsor Protocol Number: BergenPsychosisProject2 | Start Date*: 2011-04-14 | |||||||||||
Sponsor Name:Haukeland University Hospital, Division of Psychiatry | |||||||||||||
Full Title: The Bergen Psychosis Project 2 | |||||||||||||
Medical condition: Patients with schizophrenia and related non-affective psychotic disorders, corresponding to ICD-10 diagnoses F10.5-19.5, and F20-29. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003673-10 | Sponsor Protocol Number: AV003 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Bond Avillion 2 Development LP | ||||||||||||||||||
Full Title: A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in S... | ||||||||||||||||||
Medical condition: Moderate to severe asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) SK (Completed) ES (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003290-15 | Sponsor Protocol Number: GTI1503 | Start Date*: 2016-05-12 | |||||||||||||||||||||
Sponsor Name:Grifols Therapeutics Inc. | |||||||||||||||||||||||
Full Title: A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency | |||||||||||||||||||||||
Medical condition: Primary Immunodeficiency (PI) diseases | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) CZ (Completed) ES (Completed) DE (Completed) PL (Completed) HU (Completed) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002154-36 | Sponsor Protocol Number: CIGE025F1301 | Start Date*: 2019-02-13 | ||||||||||||||||
Sponsor Name:Novartis Pharma KK | ||||||||||||||||||
Full Title: A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled... | ||||||||||||||||||
Medical condition: Severe Japanese cedar pollinosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004730-25 | Sponsor Protocol Number: ACT 402 | Start Date*: 2009-05-27 | |||||||||||
Sponsor Name:INEOS Healthcare Limited | |||||||||||||
Full Title: An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia. | |||||||||||||
Medical condition: Hyperphosphataemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) BE (Completed) GB (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) LT (Completed) BG (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002004-24 | Sponsor Protocol Number: CV185-316 | Start Date*: 2017-02-08 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillatio... | |||||||||||||||||||||||
Medical condition: Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NO (Completed) BG (Completed) AT (Completed) BE (Completed) DK (Completed) NL (Completed) PL (Completed) PT (Completed) ES (Completed) CZ (Completed) DE (Completed) SE (Completed) SK (Completed) GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-015507-52 | Sponsor Protocol Number: CLBH589D2308 | Start Date*: 2009-11-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma | |||||||||||||
Medical condition: Multiple Myeloma (MM), relapsed or relapsed-and-refractory | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) IT (Completed) FR (Completed) ES (Completed) CZ (Completed) PL (Completed) GB (Completed) AT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000284-24 | Sponsor Protocol Number: B5381012 | Start Date*: 2020-02-03 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA® IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS. | |||||||||||||
Medical condition: Moderately to severely active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001335-30 | Sponsor Protocol Number: N0S103325 | Start Date*: 2005-12-07 | |||||||||||
Sponsor Name:GlaxoSmithKline R&D | |||||||||||||
Full Title: A Multicentre, Two-Part, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy,Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up... | |||||||||||||
Medical condition: Prophylaxis of migraine headache | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) BE (Completed) FI (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008753-33 | Sponsor Protocol Number: CARISNPP2003 | Start Date*: 2009-04-23 | |||||||||||
Sponsor Name:Janssen Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase | |||||||||||||
Medical condition: Neuropathic Pain in Diabetic Peripheral Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) PT (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002355-15 | Sponsor Protocol Number: CACZ885G1301 | Start Date*: 2018-12-19 | ||||||||||||||||
Sponsor Name:Novartis pharma AG | ||||||||||||||||||
Full Title: An open label, single-arm, active-treatment, efficacy and safety study of canakinumab (ACZ885) administered for at least 48 weeks in Japanese patients with Systemic Juvenile Idiopathic Arthritis (S... | ||||||||||||||||||
Medical condition: Systemic JuvenileIdiopathic Arthritis (SJIA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
